Grufity logoGrufity logo

GMDA

1.49USD-0.02(-1.32%)Delayedas of 29 Nov 2022, 02:52 pm

Gamida Cell Ltd

Market Summary

USD1.49-0.02Delayedas of 29 Nov 2022, 02:52 pm
-1.32%

GMDA Stock Price

RSI Chart

Valuation

Market Cap

100.2M

Price/Earnings

-1.12

Price/Cashflow

-1.23

MarketCap/EBT

-0.98

Price/Sales

Profitability

Return on Equity

-1.1K%

Return on Assets

-82.61%

Fundamentals

Revenue

Earnings

Earnings (TTM)

-87.4M

Earnings Y/Y

21.24%

Earnings Q/Q

8.25%

Price Action

52 Week Range

1.323.66
(Low)(High)

Last 7 days

-15.2%

Last 30 days

-9.6%

Last 90 days

-44.7%

Financial Health

Current Ratio

2.57

Investor Care

Shares Dilution (1Y)

1.22%

Diluted EPS (TTM)

1.25

Financials for Gamida Cell

Income Statement (Last 12 Months)
Description(%) Q/Q2021Q32021Q22020Q42020Q32020Q2
RevenueNaN%nullnullnullnullnull
  S&GA Expenses19.9%16,770,66713,992,00012,167,000
  R&D Expenses5.2%52,773,33350,184,00041,385,000
Earnings Before Taxes-7.1%-97,626,666.67-91,117,333.33-72,704,000.00-59,614,000.00-60,220,000.00
Net Income--83,541,000.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets5.8%114108125149165
  Current Assets9.3%63577399124
    Cash Equivalents45.3%5538425681
  Net PPE5.2%4038383530
  Current Liabilities1.9%2322202524
Shareholder's Equity72.8%148254446
  Retained Earnings--335.23----
  Additional Paid-In Capital6.1%407384382381-
Shares Outstanding24.0%74606060-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations3.6%-78.60-81.52-87.45-81.76-73.37
  Share Based Compensation4.3%55544
Cashflow From Investing54.4%2717-46.30-60.92-58.64
Cashflow From Financing1396.6%272171139

Risks

What is the probability of a big loss on GMDA?

96.0%


Probability that Gamida Cell stock will be more than 20% underwater in next one year

95.4%


Probability that Gamida Cell stock will be more than 30% underwater in next one year.

70.2%


Probability that Gamida Cell stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GMDA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Gamida Cell was unfortunately bought at previous high price.

Returns

Cumulative Returns on GMDA

-33.4%


3-Year Cumulative Returns

Which funds bought or sold GMDA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
STATE STREET CORP
SOLD OFF
-100
-131,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD
NEW
-
3,800,000
3,800,000
0.32%
2022-11-15
Balyasny Asset Management LLC
NEW
-
17,000
17,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-79.02
-1,849
429
-%
2022-11-15
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD
NEW
-
1,378,000
1,378,000
0.32%
2022-11-14
BANK OF AMERICA CORP /DE/
REDUCED
-99.2
-27,000
-
-%
2022-11-14
ADVISOR GROUP HOLDINGS, INC.
UNCHANGED
-
-
1,000
-%
2022-11-14
Wagner Wealth Management, LLC
UNCHANGED
-
-
-
-%
2022-11-14
Walleye Capital LLC
REDUCED
-54.94
-186,000
126,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying GMDA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GMDA

Gamida Cell News

InvestorsObserver

Should You Buy Gamida Cell Ltd (GMDA) Stock on Monday?.25 hours ago

GMDA Fair Value

Recent SEC filings of Gamida Cell

View All Filings
Date Filed Form Type Document
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 21, 2022
8-K
Current Report
Nov 15, 2022
SC 13D/A
13D - Major Acquisition
Nov 14, 2022
10-Q
Quarterly Report
Nov 14, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for GMDA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-18
Tomasello Shawn
ACQUIRED
-
-
2,000
-
2022-11-18
Blum Robert I
ACQUIRED
-
-
2,000
-
2022-11-18
ADAMS JULIAN
ACQUIRED
-
-
2,000
-
2022-11-18
WILLS STEPHEN T
ACQUIRED
-
-
2,000
-
2022-11-18
MOCH KENNETH I
ACQUIRED
-
-
2,000
-
2022-09-19
Jenkins Abigail L.
ACQUIRED
-
-
250,000
President and CEO
2022-07-27
ADAMS JULIAN
ACQUIRED
-
-
117,300
Chief Executive Officer
2022-06-09
Borrello Ivan M.
ACQUIRED
-
-
4,000
-
2022-01-28
Cohen-Dayag Anat
ACQUIRED
-
-
4,000
-
2022-01-28
Lankry Shai
ACQUIRED
-
-
43,000
Chief Financial Officer

1–10 of 13

Julian Adams
170
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

GMDA Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Research and development expenses, net$ 9,864$ 11,725$ 31,732$ 36,435
Commercial expenses2,7605,7559,83214,974
General and administrative expenses4,4375,00112,86612,388
Total operating loss17,06122,48154,43063,797
Financial expenses, net7416922,1492,119
Loss$ 17,802$ 23,173$ 56,579$ 65,916
Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)$ 0.29$ 0.39$ 0.95$ 1.11
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)60,440,76559,281,24359,821,65559,219,757

GMDA Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 55,071$ 55,892
Marketable securities6,22440,034
Prepaid expenses and other current assets1,4082,688
Total current assets62,70398,614
NON-CURRENT ASSETS:  
Restricted deposits3,5563,961
Property, plant and equipment, net39,94035,180
Operating lease right-of-use assets5,4597,236
Severance pay fund1,5952,148
Other long-term assets1,0591,647
Total non-current assets51,60950,172
Total assets114,312148,786
CURRENT LIABILITIES:  
Trade payables1,9168,272
Employees and payroll accruals5,6894,957
Operating lease liabilities1,8802,699
Accrued interest of convertible senior notes5511,640
Accrued expenses and other current liabilities12,6777,865
Total current liabilities22,71325,433
NON-CURRENT LIABILITIES:  
Convertible senior notes, net71,99971,417
Accrued severance pay1,8652,396
Long-term operating lease liabilities4,1745,603
Total non-current liabilities78,03879,416
CONTINGENT LIABILITIES AND COMMITMENTS
Share capital -  
Ordinary shares of NIS 0.01 par value - Authorized: 150,000,000 shares at September 30, 2022 (unaudited) and December 31, 2021; Issued 74,466,580 and 59,970,389 at September 30, 2022 (unaudited) and December 31, 2021 respectively; Outstanding: 74,380,810 and 59,970,389 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively210169
Treasury ordinary shares of NIS 0.01 par value - 85,770 and 0 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively[1]
Additional paid-in capital407,387381,225
Accumulated deficit(394,036)(337,457)
Total shareholders’ equity13,56143,937
Total liabilities and shareholders’ equity$ 114,312$ 148,786
[1]Represents an amount lower than $1.